Neoplasms

Blood and Lymph Conditions

All Conditions

Symptoms and General Pathology

Rare Diseases

Leukemia

Acute Disease

Neoplasms by Histologic Type

Hematologic Diseases

Disease Attributes

Acute Graft Versus Host Disease

Phase 1: Dose finding Phase 2: Optimal dose identified by phase 1 (dose finding) administrated to subject.

LBS-007

Lin BioScience Clinical Operations

The most common types of acute leukaemia are acute lymphoblastic leukaemia (ALL) and acute myeloid leukaemia (AML). AML is a heterogenous clonal disorder of haemopoietic progenitor cells and the most common and severe malignant leukemia in adults and is responsible for the highest mortality from leukemia. ALL is a neoplasm characterized by the growth of malignant lymphoblasts of the B or T lineage, leading to an inhibition of proliferation of the normal blood cell lineages.

The primary objectives of this study are investigating the safety, tolerability, and the MTD of LBS-007. The secondary objectives are to assess the efficacy and to determine the pharmacokinetics (PK) of LBS-007. The exploratory objective is to study and correlate the changes in surrogate biomarkers in response to treatment.

The Safety and Tolerability of LBS-007 in Patients With Relapsed or Resistant Acute Leukaemias

A Phase 1/2, Open-label, Dose Escalation and Expansion Study to Evaluate the Safety and Tolerability of LBS-007 in Patients With Relapsed or Resistant Acute Leukaemias

Lin BioScience Pty Ltd

Lin BioScience, Inc

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization	Link
The Safety and Tolerability of LBS-007 in Patients With Relapsed or Resistant Acute Leukaemias	NCT05756322	Relapsed or Res...	LBS-007	18 Years - 120 Years	Lin BioScience, Inc
The Safety and Tolerability of LBS-007 in Patients With Relapsed or Resistant Acute Leukaemias	NCT05756322	Relapsed or Res...	LBS-007	18 Years - 120 Years	Lin BioScience, Inc

Spots Global Cancer Trial Database for cdc7 inhibitor